Paris, France and Cambridge, MA – July 25^th, 2019 – Tersan Pharmaceuticals Ltd (Paris, France and Cambridge, MA), a leading digital health company focused on developing advanced Artificial Intelligence technologies for patient stratification in clinical trials, today announced that Tersan Pharmaceuticals Ltd’s work was showcased during three oral presentations at the AAIC 2019 in Los Angeles, the world’s largest Alzheimer’s disease event.

Presentation 1 showcased new clinical data identifying gut microbiota biomarkers associated with improved clinical response in patients treated with ANAVEX®2-73, a novel class of orally available selective sigma-1 receptor agonist. A growing body of evidence identifies gut microbiota as a critical component of healthy brain function, characterized as the ‘gut-brain axis’. High relative abundance of one gut microbiota family and one genus linked to improved responses with ANAVEX®2-73. The effect may be reversal of the microbiota imbalances already documented in Alzheimer’s disease patients and have a homeostatic effect on the brain-gut-microbiota axis. [Anavex Press Release PDF]

Presentations 2 and 3 provided results from a data-driven KEM® analyses of an extensively characterized cohort of subjects having subjective memory complaints (SMC), but not displaying cognitive or memory impairments. KEM® successfully identified genomic biomarkers linked to changes in cognitive tests [3] and brain images [4] characteristic of early impairment. “We identified an homozygous variant, in a gene involved in the Golgi apparatus, to be significantly linked with change of the resting state activity in the orbito-frontal cortex” stated Frédéric Parmentier, PhD, Director Data Science at Tersan Pharmaceuticals Ltd. “I strongly believe that unsupervised and explainable Artificial Intelligence are essential tools for uncovering hidden relations from complex datasets”. KEM® implements an unsupervised and explainable AI (XAI) approach to uncover pertinent and clinically actionable hypotheses from complex datasets integrating heterogeneous information.

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading digital health Company focused on developing advanced therapeutic decision support systems. Using its KEM® Explainable Artificial Intelligence (XAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and identify best clinical endpoints, best responders and best potential synergistic drugs. Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as FACS), microbiota, Patient Reported Outcomes as well as Real World Evidence data. Combining advanced data analytics with regulatory expertise, Tersan helps translate findings into innovative clinical plans. With a growing number of successful therapeutic development applications, KEM® is the only FDA-reviewed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology treatment selection system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.tersanpharm.com.